Načítá se...
MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric Aβ(25‐35)‐induced anxiety and cognitive deficits in a mouse model
AIMS: Recently, histone deacetylase (HDAC) inhibitors are considered a possible therapeutic strategy in Alzheimer's disease (AD). However, HDACi treatments exhibit diverse functions with unfavorable effects in AD. Thus, the development of selective HDACi without side effects is urgently needed....
Uloženo v:
| Vydáno v: | CNS Neurosci Ther |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6488906/ https://ncbi.nlm.nih.gov/pubmed/29978554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.13029 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|